Heart Failure (HF) remains a leading cause of morbidity and mortality worldwide despite major advances in guideline-directed medical therapy. Metabolic remodeling with impaired myocardial energy utilization has emerged as an important therapeutic target in HF. Trimetazidine, a metabolic modulator that partially inhibit...
Akshyaya Pradhan, Sudesh Prajapathi, K. Mahajan et al.· Pharmaceuticals· 0 citations
The results demonstrate that obicetrapib significantly reduces LDL cholesterol by 30–50%, apolipoprotein B by 20–30% and lipoprotein(a) by as much as 40-50%, while elevating HDL cholesterol levels by more than 100%.
P. Thandi, Akshyaya Pradhan, R. Agarwala et al.· European Cardiology· 0 citations
Resistant hypertension (RH) is a high-risk phenotype associated with increased cardiovascular and renal morbidity despite multidrug therapy. Dysregulation of the renin–angiotensin–aldosterone system (RAAS), particularly excess aldosterone activity, plays a central role in the pathophysiology of RH. Although conventiona...
Akshyaya Pradhan, M. Bhandari, Abhishek Singh et al.· Life· 0 citations
TTE-derived EAT thickness correlates with volumetric EAT and is consistently associated with major CV phenotypes, and standardization and prospective outcome-driven validation are required before routine clinical implementation.
Barbara Pala, M. Piscione, F. Cribari et al.· Current Obesity Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
